Give Kids a Chance Act of 2025

Bill 119 s 932, also known as the Pediatric Cancer Targeted Therapy Act, aims to make important changes to the Federal Food, Drug, and Cosmetic Act in order to improve the investigation and treatment of pediatric cancer through molecularly targeted therapies.

The bill specifically focuses on the development and approval process for drugs that target specific molecular pathways in pediatric cancer patients. These targeted therapies have shown promise in treating certain types of cancer by attacking the specific genetic mutations that drive the growth of cancer cells.

One of the key provisions of the bill is to streamline the regulatory process for these targeted therapies, making it easier for pharmaceutical companies to conduct clinical trials and seek approval for pediatric cancer treatments. This is intended to speed up the availability of potentially life-saving drugs for children with cancer. Additionally, the bill includes provisions to encourage collaboration between researchers, clinicians, and pharmaceutical companies in the development of targeted therapies for pediatric cancer. This collaboration is seen as crucial in advancing the field of pediatric oncology and improving outcomes for young cancer patients. Overall, Bill 119 s 932 aims to address the unique challenges and needs of pediatric cancer research and treatment by promoting the development of molecularly targeted therapies and fostering collaboration among key stakeholders in the fight against childhood cancer.